MAP7D3

Across TCGA pan-cancer cohorts, MAP7D3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAP7D3 data layer compared with 27 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAP7D3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAP7D3 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

LUAD, HNSC, and GBM are the cancer types where MAP7D3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.238	0.804	<.001	18	view →
HNSC	DFS	Quartile	All	0.653	0.860	.028	6	view →
GBM	OS	Quartile	All	0.604	0.162	.017	5	view →
CCRCC	OS	Tertile	All	0.749	0.961	.017	3	view →
LSCC	DFS	Median	III,IV	0.488	0.804	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAP7D3–LUAD (DFS)

Open the LUAD breakdown →